These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18949717)

  • 1. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.
    Chmielewski M; Carrero JJ; Nordfors L; Lindholm B; Stenvinkel P
    J Nephrol; 2008; 21(5):635-44. PubMed ID: 18949717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs.
    Nogueira J; Weir M
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):766-85. PubMed ID: 17699494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney disease and cardiovascular disease: implications of dyslipidemia.
    Keane WF; Lyle PA
    Cardiol Clin; 2005 Aug; 23(3):363-72. PubMed ID: 16084284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk.
    Wanner C; Drechsler C; Krane V
    J Ren Nutr; 2007 Jan; 17(1):75-8. PubMed ID: 17198938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic tools for dyslipidemia in peritoneal dialysis patients.
    Scarpioni R
    J Nephrol; 2009; 22(1):46-58. PubMed ID: 19229818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into lipid metabolism in chronic kidney disease: what are the practical implications?
    Kaysen GA
    Blood Purif; 2009; 27(1):86-91. PubMed ID: 19169024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid metabolism in dialysis patients-the story gets more complicated.
    Ponda MP; Barash I
    Semin Dial; 2008; 21(5):390-4. PubMed ID: 18764791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment.
    Lacquaniti A; Bolignano D; Donato V; Bono C; Fazio MR; Buemi M
    Kidney Blood Press Res; 2010; 33(2):100-10. PubMed ID: 20357496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia of kidney disease.
    Attman PO; Samuelsson O
    Curr Opin Lipidol; 2009 Aug; 20(4):293-9. PubMed ID: 19512921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.
    Benner D
    Nephrol Nurs J; 2005; 32(3):337-8. PubMed ID: 16035475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy.
    Valavi E; Otukesh H; Fereshtehnejad SM; Sharifian M
    Pediatr Transplant; 2008 Nov; 12(7):748-54. PubMed ID: 18503482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
    Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
    Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.